Simmy Pinto, MD
Pulmonary Disease · Melbourne, FLNPI 1235197781
Payments from drug & device makers
Across 616 payments — averaging $314.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SNAP Diagnostics LLC$179K
- GSK$2K
- Chiesi USA, Inc.$2K
- Grifols USA, LLC$1K
- AstraZeneca$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- plus $7K from 32 others
Across 10 payments — averaging $185.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi Pasteur Inc.$2K
What the payments were for
- Speaking & faculty fees$179,00093%
- Travel & lodging$1,6671%
- Food & beverage$12,7177%
- Education$850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SNAP Diagnostics LLC | 6 | $179,000 |
| GSK | 117 | $1,865 |
| Chiesi USA, Inc. | 2 | $1,756 |
| Grifols USA, LLC | 68 | $1,392 |
| AstraZeneca | 42 | $1,279 |
| Takeda Pharmaceuticals U.S.A., Inc. | 43 | $1,224 |
| Harmony Biosciences LLC | 31 | $1,175 |
| Philips North America LLC | 57 | $1,141 |
| Boehringer Ingelheim | 55 | $1,051 |
| Inogen, Inc. | 51 | $809 |
| Actelion Pharmaceuticals US, Inc. | 20 | $530 |
| Genentech USA, Inc. | 37 | $422 |
| Mylan Specialty L.p. | 14 | $311 |
| Insmed, Inc. | 13 | $248 |
| Inspire Medical Systems, Inc. | 4 | $213 |
| Jazz Pharmaceuticals Inc. | 9 | $164 |
| Shire North American Group Inc | 6 | $124 |
| Sunovion Pharmaceuticals Inc. | 5 | $96 |
| Merck | 5 | $86 |
| Eisai Inc. | 4 | $68 |
| Fisher & Paykel Healthcare Inc | 3 | $58 |
| United Therapeutics Corporation | 3 | $52 |
| Sanofi | 2 | $51 |
| Lilly USA, LLC | 1 | $45 |
| Electromed, Inc. | 2 | $38 |
| Bayer | 2 | $32 |
| Advanced Respiratory, Inc | 2 | $30 |
| Circassia Inc. | 2 | $29 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $24 |
| Baxter Healthcare | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Resmed Corp | 1 | $16 |
| Novartis | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Phadia US Inc. | 1 | $15 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SNAP Diagnostics study$131,750
- BREZTRI$635
- AIRSUPRA$252
- FASENRA$252
- TRELEGY ELLIPTA$125
- SYMBICORT$124
- AREXVY$110
- Inspire$106
- NUCALA$104
How this compares
$193,469 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 874 | $808,686 |
| OfevNintedanib Esylate | 16 | $208,267 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $165,849 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 141 | $150,120 |
| Spiriva RespimatTiotropium Bromide | 109 | $113,058 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 147 | $103,994 |
| WakixPitolisant Hcl | 12 | $88,331 |
| Breo ElliptaFluticasone/Vilanterol | 109 | $75,143 |
| TezspireTezepelumab-Ekko | 16 | $70,203 |
| Arnuity ElliptaFluticasone Furoate | 170 | $49,706 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 920 | $37,256 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 37 | $30,771 |
| SymbicortBudesonide/Formoterol Fumarate | 96 | $30,497 |
| Advair HfaFluticasone Propion/Salmeterol | 34 | $25,167 |
| SunosiSolriamfetol Hcl | 29 | $25,145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,865 | $1,061,8311,334 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $1,051 | $375,805184 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $1,279 | $250,821253 claims |
| Grifols USA, LLCProlastin C | $1,392 | $165,84912 claims |
| Harmony Biosciences LLCWakix | $1,175 | $88,33112 claims |
| Axsome Therapeutics, Inc.Sunosi | $15 | $25,14529 claims |
| MerckDulera | $86 | $11,04521 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $20 | $5,31016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Melbourne
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
- Neal WarshoffLoxahatchee$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.